<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.30.2" />
  <meta name="author" content="Wei Qian">
  <meta name="description" content="Assiatant Researcher of Statistics">

  
  <link rel="alternate" hreflang="en-us" href="https://allyqian.github.io/publication/2014-2/">

  
  


  

  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.1/css/academicons.min.css" integrity="sha512-NThgw3XKQ1absAahW6to7Ey42uycrVvfNfyjqcFNgCmOCQ5AR4AO0SiXrN+8ZtYeappp56lk1WtvjVmEa+VR6A==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  

  
  <link rel="alternate" href="https://allyqian.github.io/index.xml" type="application/rss+xml" title="Wei Qian&#39;s Website">
  <link rel="feed" href="https://allyqian.github.io/index.xml" type="application/rss+xml" title="Wei Qian&#39;s Website">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="https://allyqian.github.io/publication/2014-2/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="og:site_name" content="Wei Qian&#39;s Website">
  <meta property="og:url" content="https://allyqian.github.io/publication/2014-2/">
  <meta property="og:title" content="Concurrent use of anti-VEGF and anti-EGFR antibody in patients with colorectal cancer: A meta-analysis of randomized controlled trials. | Wei Qian&#39;s Website">
  <meta property="og:description" content="Objective : To systematically evaluate the efficacy and safety of the concurrent use of anti-VEGF and anti-EGFR antibodies in patients with metastatic colorectal cancer. Methods: PubMed/MEDLINE，Ovid/EMBASE, Cochrane and some other databases together with related meeting abstracts were searched for randomized controlled trials on this topic by two independent researchers. Data were extracted from the included studies and analyzed using Review Manager 5.0.23. Results: A total of 2059 patients in five studies were included in this Meta-analysis. Compared with the control treatment involving an anti-VEGF or anti-EGFR antibody alone, the concurrent use of anti-VEGF and anti-EGFR antibodies decreased the progression-free survival (RR=1.12, 95% CI: 1.05-1.19). Patients in the two treatment groups did not differ significantly in either overall survival (RR=1.17, 95% CI: 0.98-1.40) or overall response rate (RR=0.97, 95% CI: 0.89-1.07). There were significant differences between the two groups in grade 3/4 adverse cutaneous events (RR=12.62, 95% CI: 1.90-83.84), grade 3/4 infection (RR=1.53, 95% CI: 1.13-2.08), grade 3/4 hypertension (RR=0.61, 95% CI: 0.42-0.87), and grade 3/4 adverse events of nervous system (RR=0.54, 95% CI: 0.37-0.80) but not in grade 3/4 adverse gastrointestinal events (RR=1.48, 95% CI: 0.79-2.77) and grade 3/4 venous thrombosis (RR=1.18, 95% CI: 0.84-1.65). Conclusion: The concurrent use of anti-VEGF and anti-EGFR antibodies offer no additional benefits for patients with metastatic colorectal cancer as compared with the use of theses antibodies each alone and therefore should not be recommended in clinics.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2014-01-01T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2014-01-01T00:00:00&#43;00:00">
  

  

  <title>Concurrent use of anti-VEGF and anti-EGFR antibody in patients with colorectal cancer: A meta-analysis of randomized controlled trials. | Wei Qian&#39;s Website</title>

</head>
<body id="top" data-spy="scroll" data-target="#navbar-main" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">Wei Qian&#39;s Website</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      <ul class="nav navbar-nav navbar-right">
        

        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
          </a>
        </li>

        
        

        

        <li class="nav-item">
          <a href="/#research">
            
            <span>Research</span>
          </a>
        </li>

        
        

        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
          </a>
        </li>

        
        

        

        <li class="nav-item">
          <a href="/#skills">
            
            <span>Skills</span>
          </a>
        </li>

        
        

        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
          </a>
        </li>

        
        

        
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  


  <div class="container pub-title">
    <h1 itemprop="name">Concurrent use of anti-VEGF and anti-EGFR antibody in patients with colorectal cancer: A meta-analysis of randomized controlled trials.</h1>
    <span class="pub-authors" itemprop="author">
      
      <code>Qian W</code>, Chen GC, Zhang YZ, Zhu W, Li ZS, Cai QC
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Concurrent%20use%20of%20anti-VEGF%20and%20anti-EGFR%20antibody%20in%20patients%20with%20colorectal%20cancer%3a%20A%20meta-analysis%20of%20randomized%20controlled%20trials.&amp;url=https%3a%2f%2fallyqian.github.io%2fpublication%2f2014-2%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=https%3a%2f%2fallyqian.github.io%2fpublication%2f2014-2%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https%3a%2f%2fallyqian.github.io%2fpublication%2f2014-2%2f&amp;title=Concurrent%20use%20of%20anti-VEGF%20and%20anti-EGFR%20antibody%20in%20patients%20with%20colorectal%20cancer%3a%20A%20meta-analysis%20of%20randomized%20controlled%20trials."
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=https%3a%2f%2fallyqian.github.io%2fpublication%2f2014-2%2f&amp;title=Concurrent%20use%20of%20anti-VEGF%20and%20anti-EGFR%20antibody%20in%20patients%20with%20colorectal%20cancer%3a%20A%20meta-analysis%20of%20randomized%20controlled%20trials."
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Concurrent%20use%20of%20anti-VEGF%20and%20anti-EGFR%20antibody%20in%20patients%20with%20colorectal%20cancer%3a%20A%20meta-analysis%20of%20randomized%20controlled%20trials.&amp;body=https%3a%2f%2fallyqian.github.io%2fpublication%2f2014-2%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>
  </div>

  <div class="article-container">

    

    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">Objective : To systematically evaluate the efficacy and safety of the concurrent use of anti-VEGF and anti-EGFR antibodies in patients with metastatic colorectal cancer. Methods: PubMed/MEDLINE，Ovid/EMBASE, Cochrane and some other databases together with related meeting abstracts were searched for randomized controlled trials on this topic by two independent researchers. Data were extracted from the included studies and analyzed using Review Manager 5.0.23. Results: A total of 2059 patients in five studies were included in this Meta-analysis. Compared with the control treatment involving an anti-VEGF or anti-EGFR antibody alone, the concurrent use of anti-VEGF and anti-EGFR antibodies decreased the progression-free survival (RR=1.12, 95% CI: 1.05-1.19). Patients in the two treatment groups did not differ significantly in either overall survival (RR=1.17, 95% CI: 0.98-1.40) or overall response rate (RR=0.97, 95% CI: 0.89-1.07). There were significant differences between the two groups in grade <sup>3</sup>&frasl;<sub>4</sub> adverse cutaneous events (RR=12.62, 95% CI: 1.90-83.84), grade <sup>3</sup>&frasl;<sub>4</sub> infection (RR=1.53, 95% CI: 1.13-2.08), grade <sup>3</sup>&frasl;<sub>4</sub> hypertension (RR=0.61, 95% CI: 0.42-0.87), and grade <sup>3</sup>&frasl;<sub>4</sub> adverse events of nervous system (RR=0.54, 95% CI: 0.37-0.80) but not in grade <sup>3</sup>&frasl;<sub>4</sub> adverse gastrointestinal events (RR=1.48, 95% CI: 0.79-2.77) and grade <sup>3</sup>&frasl;<sub>4</sub> venous thrombosis (RR=1.18, 95% CI: 0.84-1.65). Conclusion: The concurrent use of anti-VEGF and anti-EGFR antibodies offer no additional benefits for patients with metastatic colorectal cancer as compared with the use of theses antibodies each alone and therefore should not be recommended in clinics.</p>

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#2">
              Journal
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9">Chinese Journal of Cancer Biotherapy</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            January, 2014
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            



















          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"></div>

    


  </div>
</div>

<div class="container">
  <nav>
  <ul class="pager">
    
    <li class="previous"><a href="https://allyqian.github.io/publication/2014-5/"><span
      aria-hidden="true">&larr;</span> Expression and significance of acid-sensing ion channel 3 in rats with gastroesophageal reflux disease.</a></li>
    

    
    <li class="next"><a href="https://allyqian.github.io/publication/2014-1/">Assessment of cauda equina syndrome progression pattern to improve diagnosis. <span
      aria-hidden="true">&rarr;</span></a></li>
    
  </ul>
</nav>

</div>

<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

